First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models
March 23, 2020
Study highlights previously untapped potential of genetically engineered macrophages in immunotherapy for solid tumors
PHILADELPHIA, March 23, 2020 /PRNewswire/ — Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Nature Biotechnology has published a study from the Perelman School of Medicine at the University of Pennsylvania demonstrating Carisma’s foundational technology evaluating the potential of human chimeric antigen receptor macrophages (CAR-M) for cancer immunotherapy. The preclinical findings, outlined in “Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy,” indicate that CAR-M therapy could overcome the key challenges that cell therapies have encountered with solid tumors – limited trafficking to the tumor site, an immunosuppressive tumor microenvironment, and the heterogeneous expression of tumor-associated antigens.
Full news article can be found here.